Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HSIC US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Henry Schein Inc(HSIC US)

$88.74+0.330.37%Ext:$88.47-0.270.31%(Pre-Market · 09:52:03 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HSIC US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Henry Schein Inc(HSIC US)

$88.74+0.330.37%Ext:$88.47-0.270.31%(Pre-Market · 09:52:03 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Henry Schein Inc — Company Profile

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UQ
CEO
Frederick Lowery
Headquarters
Melville, NY, US
IPO Date
Nov 3, 1995
Employees
25,000
Website
www.henryschein.com

Key Metrics

Price
$84.88
Market Cap
$9.67B
Revenue (TTM)
$3.37B
Net Income (TTM)
$107.00M
EPS (TTM)
0.93
P/E (TTM)
24.48
P/B (TTM)
2.96
Dividend Yield
0.00%
ROE (TTM)
3.28%
ROA (TTM)
0.95%
Operating Margin
5.40%
Beta
0.59

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

Website
www.henryschein.com
Location
Melville, NY, US
Phone631 843 5500
Employees25,000
CEOFrederick Lowery
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateNov 3, 1995

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.1K)

Expand
  • Form 3Caprais Emmanuel6 Nov
  • 10-QQ3ended 26 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • 8-KHenry Schein Announces Chief Financial Officer Leadership Transition8 Oct
  • 8-KEntry into a Material Definitive Agreement22 Sep
  • Form 4Albertini Andrea9 Sep
  • Form 144BERGMAN STANLEY M14 Aug
  • SC 13GHENRY SCHEIN INC6 Aug
  • 10-QQ2ended 27 Jun 20264 Aug
  • 8-KResults of Operations and Financial Condition4 Aug
  • 8-KHenry Schein Announces Leadership Transitions30 Jul
  • Form 144HERRING JOSEPH L30 Jun
  • 11-KANNUAL REPORT OF EMPLOYEE STOCK PURCHASE, SAVINGS, AND SIMILAR PLANS18 Jun
  • Form 144BERGMAN STANLEY M16 Jun
  • Form 4DANIEL WILLIAM K15 Jun
  • SDSPECIALIZED DISCLOSURE REPORT FILED PURSUANT TO SECTION 1502 OF THE DODD-FRANK WALL STREET REFORM AND CONSUMER PROTECTION ACT RELATING TO THE USE OF CONFLICT MINERALS (RULE 13P-1)29 May
  • Form 3Murphy Kelly Ann28 May
  • Form 4/ABERGMAN STANLEY M26 May
  • Form 4BERGMAN STANLEY M22 May
  • 8-KHENRY SCHEIN ANNOUNCES THE ELECTION OF WILLIAM K. “DAN” DANIEL AS INDEPENDENT CHAIRMAN OF THE BOARD22 May

News

  • CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration10 Nov
  • Is Henry Schein (HSIC) a Solid Growth Stock? 3 Reasons to Think "Yes"5 Nov
  • Henry Schein (HSIC) Upgraded to Buy: What Does It Mean for the Stock?5 Nov
  • HSIC vs. MMSI: Which Stock Should Value Investors Buy Now?5 Nov
  • Here's Why Henry Schein (HSIC) is a Strong Growth Stock5 Nov
  • Is Henry Schein (HSIC) Stock Undervalued Right Now?5 Nov
  • Henry Schein to Participate in Upcoming Investor Conferences in November and December5 Nov
  • Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term4 Nov
  • Henry Schein, Inc. (HSIC) Q3 2026 Earnings Call Transcript3 Nov
  • What Henry Schein (HSIC) Said on Its Q3 Earnings Call3 Nov
  • Henry Schein Sees Pressure From Discretionary Dental Delays3 Nov
  • Compared to Estimates, Henry Schein (HSIC) Q3 Earnings: A Look at Key Metrics3 Nov
  • HSIC Q3 Earnings Beat, Revenues Match, '26 EPS View Up, Stock Down3 Nov
  • Henry Schein (HSIC) Tops Q3 Earnings Estimates3 Nov
  • Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance3 Nov
  • Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term30 Oct
  • Analysts Estimate Henry Schein (HSIC) to Report a Decline in Earnings: What to Look Out for27 Oct
  • Henry Schein to Report Q3 Earnings: Here's What You Should Know27 Oct
  • Henry Schein to Webcast Third Quarter 2026 Conference Call on Tuesday, November 3, 2026, at 8:00 a.m. ET20 Oct
  • Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term19 Oct

Mentions in Filings

  • … States and Europe. We commercialize our flagship Curodont® product in the United States through a hybrid model that leverages both our specialized direct sales force and extensive sales and distribution platform of <strong>Henry Schein, Inc.</strong> (“Henry Schein”), our exclusive distributor in the United States and the United Kingdom. Our U.S. commercial organization includes key account managers focused on practice acquisition and onboarding, an internal sal …
    vVARDIS Holding AGHenry Schein Inc·F-1/A - Registration statement (foreign issuer, amendment)·06 Nov·6 Nov
  • … innovation and technology officer, and recently assumed the role permanently. Goodman currently serves on the boards of Burlington Stores, CBRE and Box Partners. She previously served on the boards of Staples, CarMax, <strong>Henry Schein</strong>, Stride Rite and Reef Lifestyle, LLC and served as an advisory director at Charlesbank Capital. Earlier in her career, she was a manager at Bain & Company, a global management consulting firm, where she helped develop …
    AMERICAN PUBLIC EDUCATION INCHenry Schein Inc·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·27 Oct
  • … ty was built from 2008-2014 and sits on a 15.59-acre site with 1,123 parking spaces (4.48/1,000 SF). The buildings, C, D, and E, are part of a five-building master-planned office park. The top tenant at the Property is <strong>Henry Schein</strong> (29% NRA - 6/30/30 LXP). A COREA is in place that allows for cross parking and access. No active Association is set up to run the 12-building park. Building C was sold to an existing tenant on 4/17/2026 for a gross pri …
    COMM 2014-UBS4 Mortgage TrustHenry Schein Inc·EX-99.1 - 10-D·Q4 26·22 Oct
  • … Mars Petcare. From September 2016 to April 2020, Ms. Shoff served as President of the Clinical Diagnostics Division at Thermo Fisher Scientific Inc. From September 2009 to May 2016, Ms. Shoff held various positions at <strong>Henry Schein</strong>, a publicly traded health care product distributor, including Chief Executive Officer of the Global Animal Health and Strategic Partnership Group and President of the Global Healthcare Specialty Group. Ms. Shoff also h …
    Personalis, Inc.Henry Schein Inc·DEFM14A - Definitive proxy statement (merger)·Q4 26·21 Oct
  • … Mars Petcare. From September 2016 to April 2020, Ms. Shoff served as President of the Clinical Diagnostics Division at Thermo Fisher Scientific Inc. From September 2009 to May 2016, Ms. Shoff held various positions at <strong>Henry Schein</strong>, a publicly traded health care product distributor, including Chief Executive Officer of the Global Animal Health and Strategic Partnership Group and President of the Global Healthcare Specialty Group. Ms. Shoff also h …
    Tempus AI, Inc.Henry Schein Inc·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·21 Oct
  • … Mars Petcare. From September 2016 to April 2020, Ms. Shoff served as President of the Clinical Diagnostics Division at Thermo Fisher Scientific Inc. From September 2009 to May 2016, Ms. Shoff held various positions at <strong>Henry Schein</strong>, a publicly traded health care product distributor, including Chief Executive Officer of the Global Animal Health and Strategic Partnership Group and President of the Global Healthcare Specialty Group. Ms. Shoff also h …
    Tempus AI, Inc.Henry Schein Inc·S-4/A - Registration statement (business combination, amendment)·Q4 26·20 Oct

Key Stats

Trading

Px/Chg 1D$84.88 / -0.06%
Avg Volume1.44M
Beta0.59
Mkt Cap9.67B
FD Mkt Cap10.16B

Float

Shrs Out/Float113.92M / 91.85M
Short Float0.08%
Days to Cover5.49
Stock Repurchased$125.00M

Current Valuation

EV14.84B
EV/EBITDA14.81
EV/Sales1.11
P/B2.96
P/S0.72
FCF Yield-1.41%
ROE3.28%
ROA0.95%
Current Ratio1.36

Estimates

P/E24.48
Est P/E0.00
Est EPS1.20
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings60.4520.1821.5286.4983.6990.37
Price / Sales1.890.860.732.552.462.87
Price / Book Value2.713.152.452.402.602.96
Price / Free Cash Flow10.3721.4625.3651.1325.01-71.10
ENTERPRISE VALUE METRICS
Enterprise Value13,434.613,462.913,019.312,322.213,532.214,836.3
Enterprise Value / Sales2.861.061.063.863.944.41
Enterprise Value / EBITDA38.2913.7814.8551.9952.8657.95
Enterprise Value / EBIT54.2217.6020.7076.5477.7778.50

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue1.5%12,401.012,647.012,339.012,673.013,184.0
Gross Income1.1%3,672.33,649.03,651.03,765.03,842.0
EBITDA-1.5%1,067.7977.0877.0941.01,006.0
EBIT-5.1%858.1765.0629.0644.0695.0
Net Income-10.6%623.9538.0416.0390.0398.0
EPS (Diluted)-7.4%4.453.913.163.053.27
BALANCE SHEET
Cash & ST Inv7.2%118.0117.0171.0122.0156.0
Total Assets7.2%8,481.08,607.010,573.010,218.011,215.0
Total Liabilities14%3,805.03,936.05,420.05,381.06,421.0
Total Shareholder Equity-1.3%3,425.03,446.03,655.03,393.03,245.0
CASH FLOW
Net Operating Cash Flow8.5%709.6602.0500.0848.0712.0
Cap Ex15.2%-79.0-96.0-147.0-187.0-139.0
Free Cash Flow-2.4%630.6506.0353.0661.0573.0

Enterprise Value Bridge

Millions USD10 Nov '26
Price (As of 10 Nov '26)89.31
Basic Shares113.92
Market Cap10,173.9
Diluted Shares112.54
Fully Diluted Shares Outstanding112.54
Fully Diluted Market Cap10,050.9
+Consolidated Debt3,891.0
−In-the-Money Convertible Debt—
+Capital Leases288.0
+Operating Leases—
−Cash & Equivalents-184.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest1,572.0
+Pension Liabilities—
Enterprise Value15,452.9

Segment data

Revenue

by Products and services

  • Healthcare Distribution96%
  • Technology4%

Revenue

by Geography

  • United States100%

Related companies

Accendra Health Inc/va/

ACH US

Fuse Medical, Inc.

FZMD US

Neighpart International Corp.

NIDV US

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

Henry Schein Inc — Company Profile

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UQ
CEO
Frederick Lowery
Headquarters
Melville, NY, US
IPO Date
Nov 3, 1995
Employees
25,000
Website
www.henryschein.com

Key Metrics

Price
$84.88
Market Cap
$9.67B
Revenue (TTM)
$3.37B
Net Income (TTM)
$107.00M
EPS (TTM)
0.93
P/E (TTM)
24.48
P/B (TTM)
2.96
Dividend Yield
0.00%
ROE (TTM)
3.28%
ROA (TTM)
0.95%
Operating Margin
5.40%
Beta
0.59

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

Website
www.henryschein.com
Location
Melville, NY, US
Phone631 843 5500
Employees25,000
CEOFrederick Lowery
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateNov 3, 1995

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.1K)

Expand
  • Form 3Caprais Emmanuel6 Nov
  • 10-QQ3ended 26 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • 8-KHenry Schein Announces Chief Financial Officer Leadership Transition8 Oct
  • 8-KEntry into a Material Definitive Agreement22 Sep
  • Form 4Albertini Andrea9 Sep
  • Form 144BERGMAN STANLEY M14 Aug
  • SC 13GHENRY SCHEIN INC6 Aug
  • 10-QQ2ended 27 Jun 20264 Aug
  • 8-KResults of Operations and Financial Condition4 Aug
  • 8-KHenry Schein Announces Leadership Transitions30 Jul
  • Form 144HERRING JOSEPH L30 Jun
  • 11-KANNUAL REPORT OF EMPLOYEE STOCK PURCHASE, SAVINGS, AND SIMILAR PLANS18 Jun
  • Form 144BERGMAN STANLEY M16 Jun
  • Form 4DANIEL WILLIAM K15 Jun
  • SDSPECIALIZED DISCLOSURE REPORT FILED PURSUANT TO SECTION 1502 OF THE DODD-FRANK WALL STREET REFORM AND CONSUMER PROTECTION ACT RELATING TO THE USE OF CONFLICT MINERALS (RULE 13P-1)29 May
  • Form 3Murphy Kelly Ann28 May
  • Form 4/ABERGMAN STANLEY M26 May
  • Form 4BERGMAN STANLEY M22 May
  • 8-KHENRY SCHEIN ANNOUNCES THE ELECTION OF WILLIAM K. “DAN” DANIEL AS INDEPENDENT CHAIRMAN OF THE BOARD22 May

News

  • CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration10 Nov
  • Is Henry Schein (HSIC) a Solid Growth Stock? 3 Reasons to Think "Yes"5 Nov
  • Henry Schein (HSIC) Upgraded to Buy: What Does It Mean for the Stock?5 Nov
  • HSIC vs. MMSI: Which Stock Should Value Investors Buy Now?5 Nov
  • Here's Why Henry Schein (HSIC) is a Strong Growth Stock5 Nov
  • Is Henry Schein (HSIC) Stock Undervalued Right Now?5 Nov
  • Henry Schein to Participate in Upcoming Investor Conferences in November and December5 Nov
  • Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term4 Nov
  • Henry Schein, Inc. (HSIC) Q3 2026 Earnings Call Transcript3 Nov
  • What Henry Schein (HSIC) Said on Its Q3 Earnings Call3 Nov
  • Henry Schein Sees Pressure From Discretionary Dental Delays3 Nov
  • Compared to Estimates, Henry Schein (HSIC) Q3 Earnings: A Look at Key Metrics3 Nov
  • HSIC Q3 Earnings Beat, Revenues Match, '26 EPS View Up, Stock Down3 Nov
  • Henry Schein (HSIC) Tops Q3 Earnings Estimates3 Nov
  • Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance3 Nov
  • Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term30 Oct
  • Analysts Estimate Henry Schein (HSIC) to Report a Decline in Earnings: What to Look Out for27 Oct
  • Henry Schein to Report Q3 Earnings: Here's What You Should Know27 Oct
  • Henry Schein to Webcast Third Quarter 2026 Conference Call on Tuesday, November 3, 2026, at 8:00 a.m. ET20 Oct
  • Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term19 Oct

Mentions in Filings

  • … States and Europe. We commercialize our flagship Curodont® product in the United States through a hybrid model that leverages both our specialized direct sales force and extensive sales and distribution platform of <strong>Henry Schein, Inc.</strong> (“Henry Schein”), our exclusive distributor in the United States and the United Kingdom. Our U.S. commercial organization includes key account managers focused on practice acquisition and onboarding, an internal sal …
    vVARDIS Holding AGHenry Schein Inc·F-1/A - Registration statement (foreign issuer, amendment)·06 Nov·6 Nov
  • … innovation and technology officer, and recently assumed the role permanently. Goodman currently serves on the boards of Burlington Stores, CBRE and Box Partners. She previously served on the boards of Staples, CarMax, <strong>Henry Schein</strong>, Stride Rite and Reef Lifestyle, LLC and served as an advisory director at Charlesbank Capital. Earlier in her career, she was a manager at Bain & Company, a global management consulting firm, where she helped develop …
    AMERICAN PUBLIC EDUCATION INCHenry Schein Inc·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·27 Oct
  • … ty was built from 2008-2014 and sits on a 15.59-acre site with 1,123 parking spaces (4.48/1,000 SF). The buildings, C, D, and E, are part of a five-building master-planned office park. The top tenant at the Property is <strong>Henry Schein</strong> (29% NRA - 6/30/30 LXP). A COREA is in place that allows for cross parking and access. No active Association is set up to run the 12-building park. Building C was sold to an existing tenant on 4/17/2026 for a gross pri …
    COMM 2014-UBS4 Mortgage TrustHenry Schein Inc·EX-99.1 - 10-D·Q4 26·22 Oct
  • … Mars Petcare. From September 2016 to April 2020, Ms. Shoff served as President of the Clinical Diagnostics Division at Thermo Fisher Scientific Inc. From September 2009 to May 2016, Ms. Shoff held various positions at <strong>Henry Schein</strong>, a publicly traded health care product distributor, including Chief Executive Officer of the Global Animal Health and Strategic Partnership Group and President of the Global Healthcare Specialty Group. Ms. Shoff also h …
    Personalis, Inc.Henry Schein Inc·DEFM14A - Definitive proxy statement (merger)·Q4 26·21 Oct
  • … Mars Petcare. From September 2016 to April 2020, Ms. Shoff served as President of the Clinical Diagnostics Division at Thermo Fisher Scientific Inc. From September 2009 to May 2016, Ms. Shoff held various positions at <strong>Henry Schein</strong>, a publicly traded health care product distributor, including Chief Executive Officer of the Global Animal Health and Strategic Partnership Group and President of the Global Healthcare Specialty Group. Ms. Shoff also h …
    Tempus AI, Inc.Henry Schein Inc·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·21 Oct
  • … Mars Petcare. From September 2016 to April 2020, Ms. Shoff served as President of the Clinical Diagnostics Division at Thermo Fisher Scientific Inc. From September 2009 to May 2016, Ms. Shoff held various positions at <strong>Henry Schein</strong>, a publicly traded health care product distributor, including Chief Executive Officer of the Global Animal Health and Strategic Partnership Group and President of the Global Healthcare Specialty Group. Ms. Shoff also h …
    Tempus AI, Inc.Henry Schein Inc·S-4/A - Registration statement (business combination, amendment)·Q4 26·20 Oct

Key Stats

Trading

Px/Chg 1D$84.88 / -0.06%
Avg Volume1.44M
Beta0.59
Mkt Cap9.67B
FD Mkt Cap10.16B

Float

Shrs Out/Float113.92M / 91.85M
Short Float0.08%
Days to Cover5.49
Stock Repurchased$125.00M

Current Valuation

EV14.84B
EV/EBITDA14.81
EV/Sales1.11
P/B2.96
P/S0.72
FCF Yield-1.41%
ROE3.28%
ROA0.95%
Current Ratio1.36

Estimates

P/E24.48
Est P/E0.00
Est EPS1.20
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings60.4520.1821.5286.4983.6990.37
Price / Sales1.890.860.732.552.462.87
Price / Book Value2.713.152.452.402.602.96
Price / Free Cash Flow10.3721.4625.3651.1325.01-71.10
ENTERPRISE VALUE METRICS
Enterprise Value13,434.613,462.913,019.312,322.213,532.214,836.3
Enterprise Value / Sales2.861.061.063.863.944.41
Enterprise Value / EBITDA38.2913.7814.8551.9952.8657.95
Enterprise Value / EBIT54.2217.6020.7076.5477.7778.50

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue1.5%12,401.012,647.012,339.012,673.013,184.0
Gross Income1.1%3,672.33,649.03,651.03,765.03,842.0
EBITDA-1.5%1,067.7977.0877.0941.01,006.0
EBIT-5.1%858.1765.0629.0644.0695.0
Net Income-10.6%623.9538.0416.0390.0398.0
EPS (Diluted)-7.4%4.453.913.163.053.27
BALANCE SHEET
Cash & ST Inv7.2%118.0117.0171.0122.0156.0
Total Assets7.2%8,481.08,607.010,573.010,218.011,215.0
Total Liabilities14%3,805.03,936.05,420.05,381.06,421.0
Total Shareholder Equity-1.3%3,425.03,446.03,655.03,393.03,245.0
CASH FLOW
Net Operating Cash Flow8.5%709.6602.0500.0848.0712.0
Cap Ex15.2%-79.0-96.0-147.0-187.0-139.0
Free Cash Flow-2.4%630.6506.0353.0661.0573.0

Enterprise Value Bridge

Millions USD10 Nov '26
Price (As of 10 Nov '26)89.31
Basic Shares113.92
Market Cap10,173.9
Diluted Shares112.54
Fully Diluted Shares Outstanding112.54
Fully Diluted Market Cap10,050.9
+Consolidated Debt3,891.0
−In-the-Money Convertible Debt—
+Capital Leases288.0
+Operating Leases—
−Cash & Equivalents-184.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest1,572.0
+Pension Liabilities—
Enterprise Value15,452.9

Segment data

Revenue

by Products and services

  • Healthcare Distribution96%
  • Technology4%

Revenue

by Geography

  • United States100%

Related companies

Accendra Health Inc/va/

ACH US

Fuse Medical, Inc.

FZMD US

Neighpart International Corp.

NIDV US

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG